Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Addiction (Abingdon, England)|August 26, 2025
Counterfeit 'Xanax®' tablets: A comparative study of clinical and seizure data in Victoria, AustraliaRebekka Syrjanen, Shaun L Greene, Sarah E Hodgson, et al.
Journal of Analytical Toxicology|August 19, 2022
Intoxications in an Australian Emergency Department Involving 'Nitazene' Benzylbenzimidazole Synthetic Opioids (Etodesnitazene, Butonitazene and Protonitazene)Jennifer L Schumann, Rebekka Syrjanen, Katherine Alford, et al.
Clinical Toxicology (Philadelphia, Pa.)|July 30, 2024
Protonitazene detection in two cases of opioid toxicity following the use of tetrahydrocannabinol vape products in AustraliaRebekka Syrjanen, Jennifer L Schumann, Jared W Castle, et al.
Clinical Toxicology (Philadelphia, Pa.)|March 29, 2023
Non-fatal intoxications involving the novel benzodiazepine clonazolam: case series from the Emerging Drugs Network of Australia - Victoria projectRebekka Syrjanen, Shaun L Greene, Jared W Castle, et al.
The International Journal on Drug Policy|November 12, 2023
A risk-based approach to community illicit drug toxicosurveillance: operationalisation of the Emerging Drugs Network of Australia - Victoria (EDNAV) projectRebekka Syrjanen, Jennifer L Schumann, Tom Lyons, et al.
BMJ Open|May 14, 2020
Australian Suicide Prevention using Health-Linked Data (ASHLi): Protocol for a population-based case series studyKate M Chitty, Jennifer L Schumann, Andrea Schaffer, et al.
The Medical Journal of Australia|May 25, 2023
Psychotropic and other medicine use at time of death by suicide: a population-level analysis of linked dispensing and forensic toxicology dataKate M Chitty, Nicholas A Buckley, Jessy Lim, et al.
Drug and Alcohol Review|December 7, 2025
The Emergence of Novel Benzodiazepines in Australia, Evidence, Alerts, Clinical Management and Harm Reduction-A Narrative ReviewJack Freestone, Stassi Kypri, Jennifer L Schumann, et al.
Pageof 3